UNSPSC 51162103: Isoniazid/rifampin

This classification denotes a combination drug defined by the U.S. Department of Veterans Affairs in its (VA's) National Drug File (NDF), which falls under VA Drug Class AM500. This VA Drug Class (AM500) classifies this compound as belonging to the group ANTITUBERCULARS.

UNSPSC 51162103 Isoniazid/rifampin, a Commodity code, does not map to the pharmaceutical procurement activity appearing in recent state and local solicitations tagged under this code. The four recent opportunities instead solicit naloxone and drug deactivation systems, on-site pharmacy services, direct-to-manufacturer prescription programs, and generic multi-source pharmaceuticals and OTC products—none of which are tuberculosis-treatment medications. The code shows little relevant recent activity aligned with its nominal scope of isoniazid/rifampin combination therapy.

The mislabeled opportunities span diverse issuing bodies—Seminole County, Florida (county health services); Hall County, Georgia (employee group health insurance pharmacy services); the Texas Health and Human Services Commission (state-level RFI for prescription program redesign); and the Minnesota Multistate Cooperative Purchasing Alliance (multi-state cooperative vehicle administered by Minnesota Department of Administration). Representative recent work includes Seminole County's IFB for 1,900 units of naloxone and 800 safe drug deactivation systems annually (due July 26, 2023); Hall County's RFQ/P #47-010 for on-site pharmacy services at a family health center clinic serving approximately 3,005 eligible individuals (due June 4, 2026); and MMCAP's RFP for generic multi-source pharmaceuticals and OTC products through three authorized wholesalers (due March 26, 2026). Activity spans Florida, Georgia, Texas, Minnesota, and Oregon. Vendors pursuing work under this code taxonomy classification should verify actual commodity alignment with issuing bodies before investing in bid preparation.